How often did Belgian physicians co-prescribe tamoxifen with strong CYP2D6 inhibitors over the last 6 years?

Abstract Aims: Tamoxifen is widely used in the treatment of breast cancer. It is a pro-drug metabolized to the more active endoxifen through CYP2D6. Concomitant intake of CYP2D6 inhibitors results in lower endoxifen levels and could influence efficacy. The objective of this study was to evaluate the evolution of co-prescription of tamoxifen and CYP2D6 inhibitors in Belgium. Methods: Data were retrieved from the Pharmanet database of the National Institute for Health and Disability Insurance for the period January 2006–December 2009. For the analysis of the evolution of the co-prescription, the period was divided in subperiods of 2 months. The category tamoxifen+CYP2D6 inhibitor was defined as women who were delivered tamoxifen and a CYP2D6 inhibitor in that subperiod. The results were validated on the period December 2011–May 2012. Results: The percentage of co-prescription decreased over time for the strong CYP2D6 inhibitors and increased for the weak CYP2D6 inhibitor, with these trends persisting in 2012. Tamoxifen and CYP2D6 inhibitors were mostly prescribed by general practitioners and gynaecologists and by general practitioners and psychiatrists, respectively. Discussion: This study shows that a proportion of women taking tamoxifen in Belgium are prescribed a strong CYP2D6 inhibitor, which could affect tamoxifen efficacy. Over time, the concomitant intake decreased. Paroxetine was the most prescribed strong CYP2D6 inhibitor. Venlafaxine, a weak CYP2D6 inhibitor, was prescribed more often. This study also shows that tamoxifen and the CYP2D6 inhibitors are not only prescribed by physicians specialized in breast cancer; therefore, all physicians should be aware of this interaction.

[1]  M. Goetz,et al.  Abstract PD10-08: Venlafaxine inhibits the CYP2D6 mediated metabolic activation of tamoxifen: Results of a prospective multicenter study: (NCT00667121) , 2012 .

[2]  Erin E. Carlson,et al.  Evaluation of CYP2D6 and Efficacy of Tamoxifen and Raloxifene in Women Treated for Breast Cancer Chemoprevention: Results from the NSABP P1 and P2 Clinical Trials , 2011, Clinical Cancer Research.

[3]  S. Suissa,et al.  Concurrent use of tamoxifen with CYP2D6 inhibitors and the risk of breast cancer recurrence , 2011, Breast Cancer Research and Treatment.

[4]  K. Lunetta,et al.  CYP2D6 inhibition and breast cancer recurrence in a population-based study in Denmark. , 2011, Journal of the National Cancer Institute.

[5]  V. Stearns,et al.  Pharmacogenetics of endocrine therapy for breast cancer. , 2011, Annual review of medicine.

[6]  E. Berns,et al.  The impact of CYP2D6-predicted phenotype on tamoxifen treatment outcome in patients with metastatic breast cancer , 2010, British Journal of Cancer.

[7]  Hein Putter,et al.  Effect of concomitant CYP2D6 inhibitor use and tamoxifen adherence on breast cancer recurrence in early-stage breast cancer. , 2010, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[8]  Peter C Austin,et al.  Selective serotonin reuptake inhibitors and breast cancer mortality in women receiving tamoxifen: a population based cohort study , 2010, BMJ : British Medical Journal.

[9]  K. Lunetta,et al.  Breast cancer recurrence risk related to concurrent use of SSRI antidepressants and tamoxifen , 2010, Acta oncologica.

[10]  R. Epstein,et al.  Risk of breast cancer recurrence in women initiating tamoxifen with CYP2D6 inhibitors. , 2009, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[11]  A. Hofman,et al.  The CYP2D6*4 polymorphism affects breast cancer survival in tamoxifen users , 2009, Breast Cancer Research and Treatment.

[12]  T. Lumley,et al.  Breast cancer recurrence risk in relation to antidepressant use after diagnosis , 2008, Breast Cancer Research and Treatment.

[13]  K. Lunetta,et al.  Tamoxifen's protection against breast cancer recurrence is not reduced by concurrent use of the SSRI citalopram , 2008, British Journal of Cancer.

[14]  Zeruesenay Desta,et al.  Quantitative effect of CYP2D6 genotype and inhibitors on tamoxifen metabolism: Implication for optimization of breast cancer treatment , 2006, Clinical pharmacology and therapeutics.

[15]  David A. Flockhart,et al.  CYP2D6 genotype, antidepressant use, and tamoxifen metabolism during adjuvant breast cancer treatment. , 2005, Journal of the National Cancer Institute.

[16]  David A. Flockhart,et al.  Comprehensive Evaluation of Tamoxifen Sequential Biotransformation by the Human Cytochrome P450 System in Vitro: Prominent Roles for CYP3A and CYP2D6 , 2004, Journal of Pharmacology and Experimental Therapeutics.

[17]  Vijay S. Ramanath,et al.  Lack of Attenuation in the Antitumor Effect of Tamoxifen by Chronic CYP Isoform Inhibition , 2004, Journal of clinical pharmacology.

[18]  Zeruesenay Desta,et al.  Active tamoxifen metabolite plasma concentrations after coadministration of tamoxifen and the selective serotonin reuptake inhibitor paroxetine. , 2003, Journal of the National Cancer Institute.

[19]  Osborne Ck,et al.  Tamoxifen in the Treatment of Breast Cancer , 1998 .

[20]  S. Legha,et al.  Tamoxifen in the treatment of breast cancer. , 1988, Annals of internal medicine.

[21]  Yusuke Nakamura,et al.  Pharmacogenomics of tamoxifen: roles of drug metabolizing enzymes and transporters. , 2012, Drug metabolism and pharmacokinetics.

[22]  D. Kurnik,et al.  Potent CYP2D6 Inhibiting drugs do not increase relapse rate in early breast cancer patients treated with adjuvant tamoxifen , 2010, Breast Cancer Research and Treatment.

[23]  V. Stearns,et al.  No Increase in Breast Cancer Recurrence with Concurrent Use of Tamoxifen and Some CYP2D6-Inhibiting Medications , 2010 .

[24]  David A. Flockhart,et al.  The impact of cytochrome P450 2D6 metabolism in women receiving adjuvant tamoxifen , 2006, Breast Cancer Research and Treatment.